Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

EyeGate Pharmaceuticals, Inc.

  • Stephen From, EyeGate Pharmaceuticals, Inc.

EyeGate is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating diseases and disorders of the eye. The Company has two proprietary platform technologies.

Our most advanced platform is based on cross-linked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. We recently announced positive data from two studies for our lead CMHA-S product, EyeGate Ocular Bandage Gel (“OBG”), which is being developed for corneal re-epithelialization following photorefractive keratectomy (“PRK”) surgery, as well as for better management of patients with punctate epitheliopathies (“PE”) due to pathologies such as dry. EyeGate OBG is classified as a Class 2 medical device, which we plan to pursue U.S. regulatory clearance via the FDA’s De Novo 510(k) pathway.

  • Date:Tuesday, February 12
  • Time:10:45 AM - 11:00 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23420
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Inform and update investors
  • Company Website:www.eyegatepharma.com
  • Company HQ City:Waltham
  • Company HQ State:Massachusetts
  • Company HQ Country:United States
  • Ticker:EYEG
  • Exchange:Nasdaq
  • CEO/Top Company Official:Stephen From
  • Main Therapeutic Focus:Ophthalmology
  • Lead Product in Development:EyeGate OBG
  • Development Phase of Primary Product:Other/Not Applicable
Speakers
Stephen From
EyeGate Pharmaceuticals, Inc.
Back